The expression of histone demethylase JMJD1A in renal cell carcinoma

Neoplasma

Volumn 58, Issue 2, 2011, Pages 153-157

  Guo, X ^a,b   Shi, M ^b   Sun, L ^b   Wang, Y ^b   Gui, Y ^b   Cai, Z ^b   Duan, X ^a  

^a HEBEI NORMAL UNIVERSITY   (China)

^b PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

Author keywords

Histone demethylase; Hypoxia inducible factor; Iron; JMJD1A; Renal cell carcinoma

Indexed keywords

COBALT; HISTONE DEMETHYLASE; JMJD1A PROTEIN; NICKEL; UNCLASSIFIED DRUG; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KDM3A PROTEIN, HUMAN; MESSENGER RNA;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL; CANCER CELL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; UPREGULATION; WESTERN BLOTTING; CELL HYPOXIA; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; KIDNEY NEOPLASMS; RNA, MESSENGER;

EID: 79961109478     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_02_153     Document Type: Article

References (29)

1. LIM DL, KO R, PAUTLER SE. Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists. Can Urol Assoc J 2007; 1: S13-S20.
2. GALLOU C, JOLY D, MEJEAN A, STAROZ F, MARTIN N et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999; 13: 464-475. doi:10.1002/(SICI)10981004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A
3. MAXWELL P H, WIESENER M S, CHANG GW, CLIFFORD SC, VAUX EC et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275. doi:10.1038/20459
4. PANTUCK AJ, ZENG G, BELLDEGRUN AS, FIGLIN RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003; 9: 4641-4652.
5. KOUKOURAKIS MI, GIATROMANOLAKI A, POLYCHRONIDIS A, SIMOPOULOS C, GATTER KC et al. Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Sci 2006; 97: 582-588. doi:10.1111/j.1349-7006.2006.00220.x
6. BEYER S, KRISTENSEN MM, JENSEN KS, JOHANSEN JV, STALLER P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 2008; 283: 36542-36552. doi:10.1074/jbc. M804578200
7. WELLMANN S, BETTKOBER M, ZELMER A, SEEGER K, FAIGLE M et al. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 2008; 372: 892-897. doi:10.1016/j.bbrc.2008.05.150
8. POLLARD PJ, LOENARZ C, MOLE DR, MCDONOUGH MA, GLEADLE JM et al. Regulation of Jumonji-domaincontaining histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J 2008; 416: 387-394. doi:10.1042/ BJ20081238
9. XIA X, LEMIEUX ME, LI W, CARROLL JS, BROWN M et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 2009;106: 4260-4265. doi:10.1073/ pnas.0810067106
10. YAMANE K, TOUMAZOU C, TSUKADA Y, ERDJUMENTBROMAGE H, TEMPST P et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 2006,125: 483-495.
11. SAR A, PONJEVIC D, NGUYEN M, BOX AH, DEMETRICK DJ. Identification and characterization of demethylase JMJD1A as a gene upregulated in the human cellular response to hypoxia. Cell Tissue Res 2009; 337: 223-234. doi:10.1007/ s00441-009-0805-y
12. KRIEG AJ, RANKIN EB, CHAN D, RAZORENOVA O, FERNANDEZ S et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol 2010; 30: 344-353. doi:10.1128/MCB.00444-09
13. LIANG YX, HE HC, HAN ZD, BI XC, DAI QS et al. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer Invest 2009; 27: 788-793. doi:10.1080/07357900802709167
14. LIDGREN A, BERGH A, GRANKVIST K, RASMUSON T, LJUNGBERG B. Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int 2008; 101: 480-484.
15. VENGELLUR A, LAPRES JJ. The role of hypoxia inducible factor 1alpha in cobalt chloride induced cell death in mouse embryonic fibroblasts. Toxicol Sci 2004; 82: 638-646. doi:10.1093/toxsci/kfh278
16. KARACZYN A, IVANOV S, REYNOLDS M, ZHITKOVICH A, KASPRZAK KS et al. Ascorbate depletion mediates upregulation of hypoxia-associated proteins by cell density and nickel. J Cell Biochem 2006; 97: 1025-1035. doi:10.1002/ jcb.20705
17. SALNIKOW K, DONALD SP, BRUICK RK, ZHITKOVICH A, PHANG JM et al. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004; 279 (39): 40337-40344. doi:10.1074/jbc.M403057200
18. KLATTE T, SELIGSON DB, RIGGS SB, LEPPERT JT, BERKMAN MK et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007; 13: 7388-7393. doi:10.1158/1078-0432.CCR-07-0411
19. BALDEWIJNS MM, THIJSSEN VL, VAN DEN EYNDEN GG, VAN LAERE SJ, BLUEKENS AM et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer 2007; 96: 1888-1895. doi:10.1038/sj.bjc.6603796
20. SUÁREZ C, MORALES R, MUÑOZ E, RODÓN J, VALVERDE CM et al. Molecular basis for the treatment of renal cell carcinoma. Clin Transl Oncol 2010; 12: 15-21. doi:10.1007/s12094-010-0461-4
21. QIAN CN, HUANG D, WONDERGEM B, TEH BT. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer 2009;115: 2282-2289. doi:10.1002/cncr.24238
22. CHI P, ALLIS CD, WANG GG. Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010; 10: 457-469. doi:10.1038/ nrc2876
23. XIANG Y, ZHU Z, HAN G, YE X, XU B et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci USA 2007; 104: 19226-19231. doi:10.1073/pnas.0700735104
24. YAMANE K, TATEISHI K, KLOSE RJ, FANG J, FABRIZIO LA et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 2007; 25: 801-812. doi:10.1016/j.molcel.2007.03.001
25. HSIA DA, TEPPER CG, POCHAMPALLI MR, HSIA EY, IZUMIYA C et al. KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation. Proc Natl Acad Sci USA 2010; 107: 9671-9676. doi:10.1073/pnas.1000401107
26. MORRIS MR, HUGHES DJ, TIAN YM, RICKETTS CJ, LAU KW et al. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. Anticancer Res 2009; 29: 4337-4343.
27. LI Q, KE Q, COSTA M. Alterations of histone modifications by cobalt compounds. Carcinogenesis 2009; 30: 1243-1251. doi:10.1093/carcin/bgp088
28. CHEN H, GIRI NC, ZHANG R, YAMANE K, ZHANG Y et al. Nickel ions inhibit histone demethylase JMJD1A and DNA repair enzyme ABH2 by replacing the ferrous iron in the catalytic centers. J Biol Chem 2010; 285: 7374-7383. doi:10.1074/jbc.M109.058503
29. CHEN H, COSTA M. Ironand 2-oxoglutarate-dependent dioxygenases: an emerging group of molecular targets for nickel toxicity and carcinogenicity. Biometals 2009; 22: 191-196. doi:10.1007/s10534-008-9190-3